Clinical Infectious Diseases (CID)
Volume 61 Issue 2 July 15, 2015
http://cid.oxfordjournals.org/content/current

.
Editor’s choice: The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus
David B. Rein, John S. Wittenborn, Bryce D. Smith, Danielle K. Liffmann, and John W. Ward
Clin Infect Dis. (2015) 61 (2): 157-168 doi:10.1093/cid/civ220

.
Compared to previous treatments for hepatitis C, new treatments provide much higher cure rates with far fewer adverse effects and contraindications. This article estimates the cost-effectiveness and financial impact of new hepatitis C medications as compared to treatments of the past.
Diane M. Richardson, Elina L. Medvedeva, Christopher B. Roberts, and Darren R. Linkin for the Centers for Disease Control and Prevention Epicenter Program
Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination in Community-Dwelling Veterans
Clin Infect Dis. (2015) 61 (2): 171-176 doi:10.1093/cid/civ261
High-dose influenza vaccine was not more effective than standard-dose vaccine in protecting against hospitalization for influenza or pneumonia in patients ≥65 years of age; subgroup analysis found that it was more effective in those ≥85 years of age.